{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:18:08Z","timestamp":1793215088271,"version":"4.5.0"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:p>Patients with ischemic stroke or transient ischemic attack and non-valvular atrial fibrillation have a high risk of recurrent stroke and other vascular events. The aim of this guideline is to provide recommendations on antithrombotic medication for secondary prevention of stroke and other vascular outcomes in these patients. The working group identified questions and outcomes, graded evidence, and developed recommendations according to the Grading of Recommendations Assessment, Development, and Evaluation approach and the European Stroke Organisation (ESO) standard operating procedure for guidelines. The guideline was reviewed and approved by the ESO guideline board and the ESO executive committee. In patients with atrial fibrillation and previous stroke or transient ischemic attack, oral anticoagulants reduce the risk of recurrence over antiplatelets or no antithrombotic treatment. Non-vitamin K antagonist oral anticoagulants are preferred over vitamin K antagonists because they have a lower risk of major bleeding and death. Recommendations are weak regarding timing of treatment, (re-)starting oral anticoagulants in patients with previous intracerebral haemorrhage, and treatment in specific patient subgroups of those of older age, with cognitive impairment, renal failure or small vessel disease, because of a lack of strong evidence. In conclusion, for patients with atrial fibrillation and ischemic stroke or transient ischemic attack, non-vitamin K antagonist oral anticoagulants are the preferred treatment for secondary prevention of recurrent stroke or thromboembolism. Further research is required to determine the best timing for initiating oral anticoagulants after an acute ischemic stroke, whether or not oral anticoagulants should be (re)started in patients with a history of intracerebral haemorrhage, and the best secondary preventive treatment in specific subgroups.<\/jats:p>","DOI":"10.1177\/2396987319841187","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T21:41:46Z","timestamp":1554846106000},"page":"198-223","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":188,"title":["Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline"],"prefix":"10.1093","volume":"4","author":[{"given":"Catharina JM","family":"Klijn","sequence":"first","affiliation":[{"name":"Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Paciaroni","sequence":"additional","affiliation":[{"name":"Stroke Unit and Division of Cardiovascular Medicine, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eivind","family":"Berge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital, Oslo, Norway 4"},{"name":"Division of Brain Sciences, Imperial College London, London, UK 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Korompoki","sequence":"additional","affiliation":[{"name":"First Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece 6"},{"name":"Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janika","family":"K\u00f5rv","sequence":"additional","affiliation":[{"name":"European Stroke Organisation, Basel, Switzerland 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avtar","family":"Lal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Oslo University Hospital, Oslo, Norway 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Putaala","sequence":"additional","affiliation":[{"name":"European Stroke Organisation, Basel, Switzerland 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Werring","sequence":"additional","affiliation":[{"name":"Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, London, UK 10"},{"name":"The National Hospital for Neurology and Neurosurgery, London, UK 11"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,1]]},"reference":[{"key":"2026012113203713700_bibr1-2396987319841187","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"2026012113203713700_bibr2-2396987319841187","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijcard.2013.11.086","article-title":"Atrial fibrillation: improvement in identification and stroke preventive therapy \u2013 data from the UK Clinical Practice Research Datalink, 2000\u20132012","volume":"171","author":"Scowcroft","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026012113203713700_bibr3-2396987319841187","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/europace\/eur132","article-title":"Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections","volume":"13","author":"Stefansdottir","year":"2011","journal-title":"Europace"},{"key":"2026012113203713700_bibr4-2396987319841187","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","article-title":"Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060","volume":"34","author":"Krijthe","year":"2013","journal-title":"Eur Heart J"},{"key":"2026012113203713700_bibr5-2396987319841187","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"2026012113203713700_bibr6-2396987319841187","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","article-title":"Cryptogenic stroke and underlying atrial fibrillation","volume":"370","author":"Sanna","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012113203713700_bibr7-2396987319841187","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1056\/NEJMoa1311376","article-title":"Atrial fibrillation in patients with cryptogenic stroke","volume":"370","author":"Gladstone","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012113203713700_bibr8-2396987319841187","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1474-4422(17)30002-9","article-title":"Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial","volume":"16","author":"Wachter","year":"2017","journal-title":"Lancet Neurol"},{"key":"2026012113203713700_bibr9-2396987319841187","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/ijs.12583","article-title":"The European Stroke Organisation Guidelines: a standard operating procedure","volume":"10","author":"Ntaios","year":"2015","journal-title":"Int J Stroke"},{"key":"2026012113203713700_bibr10-2396987319841187","doi-asserted-by":"crossref","first-page":"xxi","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"2026012113203713700_bibr11-2396987319841187","first-page":"1255","article-title":"EAFT (European Atrial Fibrillation Trial) Study Group","volume":"342","author":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke","year":"1993","journal-title":"Lancet"},{"key":"2026012113203713700_bibr12-2396987319841187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"J Neurol Sci"},{"key":"2026012113203713700_bibr13-2396987319841187","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","article-title":"The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results","volume":"54","author":"Farrell","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012113203713700_bibr14-2396987319841187","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012113203713700_bibr15-2396987319841187","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"2026012113203713700_bibr16-2396987319841187","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"2026012113203713700_bibr17-2396987319841187","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Investigators AWGotA","year":"2006","journal-title":"Lancet"},{"key":"2026012113203713700_bibr18-2396987319841187","year":"1996"},{"key":"2026012113203713700_bibr19-2396987319841187","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJM199608223350802","article-title":"An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation","volume":"335","author":"Hylek","year":"1996","journal-title":"N Engl J Med"},{"key":"2026012113203713700_bibr20-2396987319841187","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial hemorrhage in outpatients taking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann Intern Med"},{"key":"2026012113203713700_bibr21-2396987319841187","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol"},{"key":"2026012113203713700_bibr22-2396987319841187","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurol"},{"key":"2026012113203713700_bibr23-2396987319841187","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial","volume":"11","author":"Easton","year":"2012","journal-title":"Lancet Neurol"},{"key":"2026012113203713700_bibr24-2396987319841187","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","article-title":"Outcomes With edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)","volume":"47","author":"Rost","year":"2016","journal-title":"Stroke"},{"key":"2026012113203713700_bibr25-2396987319841187","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2026012113203713700_bibr26-2396987319841187","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/B:THRO.0000011377.78585.63","article-title":"Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range","volume":"15","author":"Schmitt","year":"2003","journal-title":"J Thromb Thrombolysis"},{"key":"2026012113203713700_bibr27-2396987319841187","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2026012113203713700_bibr28-2396987319841187","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"2026012113203713700_bibr29-2396987319841187","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijcard.2017.06.004","article-title":"Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: a meta-analysis of randomized trials","volume":"244","author":"Carmo","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026012113203713700_bibr30-2396987319841187","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11739-015-1226-4","article-title":"Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation","volume":"10","author":"Arnao","year":"2015","journal-title":"Intern Emerg Med"},{"key":"2026012113203713700_bibr31-2396987319841187","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.25342","article-title":"Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage","volume":"84","author":"Tsivgoulis","year":"2018","journal-title":"Ann Neurol"},{"key":"2026012113203713700_bibr32-2396987319841187","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012113203713700_bibr33-2396987319841187","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(00)02085-7","article-title":"Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial","volume":"355","author":"Berge","year":"2000","journal-title":"Lancet"},{"key":"2026012113203713700_bibr34-2396987319841187","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1161\/hs1001.097093","article-title":"Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial","volume":"32","author":"Saxena","year":"2001","journal-title":"Stroke"},{"key":"2026012113203713700_bibr35-2396987319841187","first-page":"1641","article-title":"CAST (Chinese Acute Stroke Trial) Collaborative Group","volume":"349","author":"CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke","year":"1997","journal-title":"Lancet"},{"key":"2026012113203713700_bibr36-2396987319841187","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/01.STR.0000254600.92975.1f","article-title":"Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials","volume":"38","author":"Paciaroni","year":"2007","journal-title":"Stroke"},{"key":"2026012113203713700_bibr37-2396987319841187","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/STROKEAHA.115.008891","article-title":"Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study","volume":"46","author":"Paciaroni","year":"2015","journal-title":"Stroke"},{"key":"2026012113203713700_bibr38-2396987319841187","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1747493016632239","article-title":"Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: the SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study","volume":"11","author":"Arihiro","year":"2016","journal-title":"Int J Stroke"},{"key":"2026012113203713700_bibr39-2396987319841187","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1161\/STROKEAHA.116.013491","article-title":"Early rivaroxaban use after cardioembolic stroke may not result in hemorrhagic transformation: a prospective magnetic resonance imaging study","volume":"47","author":"Gioia","year":"2016","journal-title":"Stroke"},{"key":"2026012113203713700_bibr40-2396987319841187","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1212\/WNL.0000000000003283","article-title":"Early start of DOAC after ischemic stroke: risk of intracranial hemorrhage and recurrent events","volume":"87","author":"Seiffge","year":"2016","journal-title":"Neurology"},{"key":"2026012113203713700_bibr41-2396987319841187","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1161\/STROKEAHA.116.015770","article-title":"Prediction of early recurrent thromboembolic event and major bleeding in patients with acute stroke and atrial fibrillation by a risk stratification schema: the ALESSA score study","volume":"48","author":"Paciaroni","year":"2017","journal-title":"Stroke"},{"key":"2026012113203713700_bibr42-2396987319841187","author":"Wilson","year":"2018"},{"key":"2026012113203713700_bibr43-2396987319841187","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2017.2161","article-title":"Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation-related mild ischemic stroke: a randomized clinical trial","volume":"74","author":"Hong","year":"2017","journal-title":"JAMA Neurol"},{"key":"2026012113203713700_bibr44-2396987319841187","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000319048","article-title":"Symptomatic hemorrhagic transformation and its predictors in acute ischemic stroke with atrial fibrillation","volume":"64","author":"Lee","year":"2010","journal-title":"Eur Neurol"},{"key":"2026012113203713700_bibr45-2396987319841187","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1161\/STROKEAHA.107.510321","article-title":"Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study","volume":"39","author":"Paciaroni","year":"2008","journal-title":"Stroke"},{"key":"2026012113203713700_bibr46-2396987319841187","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S1474-4422(03)00558-1","article-title":"Management of acute ischaemic stroke: new guidelines from the American Stroke Association and European Stroke Initiative","volume":"2","author":"Klijn","year":"2003","journal-title":"Lancet Neurol"},{"key":"2026012113203713700_bibr47-2396987319841187","first-page":"2137","article-title":"Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"38","author":"Heidbuchel","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012113203713700_bibr48-2396987319841187","first-page":"1569","article-title":"International Stroke Trial Collaborative Group","volume":"349","author":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke.","year":"1997","journal-title":"Lancet"},{"key":"2026012113203713700_bibr49-2396987319841187","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/01.STR.31.6.1240","article-title":"Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups","volume":"31","author":"Chen","year":"2000","journal-title":"Stroke"},{"key":"2026012113203713700_bibr50-2396987319841187","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004065","article-title":"Short-term risk of bleeding during heparin bridging at initiation of vitamin K antagonist therapy in more than 90 000 patients with nonvalvular atrial fibrillation managed in outpatient care","volume":"5","author":"Bouillon","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026012113203713700_bibr51-2396987319841187","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/jth.12810","article-title":"Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis","volume":"13","author":"Kim","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2026012113203713700_bibr52-2396987319841187","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/archneur.65.9.noc70105","article-title":"Anticoagulation after cardioembolic stroke: to bridge or not to bridge?.","volume":"65","author":"Hallevi","year":"2008","journal-title":"Arch Neurol"},{"key":"2026012113203713700_bibr53-2396987319841187","first-page":"35","article-title":"Study of the efficacy, safety and tolerability of low-molecular-weight heparin vs. unfractionated heparin as bridging therapy in patients with embolic stroke due to atrial fibrillation","volume":"9","author":"Feiz","year":"2016","journal-title":"J Vasc Interv Neurol"},{"key":"2026012113203713700_bibr54-2396987319841187","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/europace\/euv069","article-title":"Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey","volume":"17","author":"Pison","year":"2015","journal-title":"Europace"},{"key":"2026012113203713700_bibr55-2396987319841187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026012113203713700_bibr56-2396987319841187","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial","volume":"312","author":"Reddy","year":"2014","journal-title":"JAMA"},{"key":"2026012113203713700_bibr57-2396987319841187","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.4244\/EIJY15M01_06","article-title":"Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug","volume":"11","author":"Tzikas","year":"2016","journal-title":"EuroIntervention"},{"key":"2026012113203713700_bibr58-2396987319841187","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.hrthm.2017.05.038","article-title":"Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial","volume":"14","author":"Boersma","year":"2017","journal-title":"Heart Rhythm"},{"key":"2026012113203713700_bibr59-2396987319841187","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)","volume":"61","author":"Reddy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012113203713700_bibr60-2396987319841187","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials","volume":"70","author":"Reddy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012113203713700_bibr61-2396987319841187","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/STROKEAHA.113.003003","article-title":"Incidence of oral anticoagulant-associated intracerebral hemorrhage in the Netherlands","volume":"45","author":"Schols","year":"2014","journal-title":"Stroke"},{"key":"2026012113203713700_bibr62-2396987319841187","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1161\/STROKEAHA.114.007953","article-title":"Influence of intracerebral hemorrhage location on incidence, characteristics, and outcome: population-based study","volume":"46","author":"Samarasekera","year":"2015","journal-title":"Stroke"},{"key":"2026012113203713700_bibr63-2396987319841187","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1212\/01.wnl.0000250340.05202.8b","article-title":"The increasing incidence of anticoagulant-associated intracerebral hemorrhage","volume":"68","author":"Flaherty","year":"2007","journal-title":"Neurology"},{"key":"2026012113203713700_bibr64-2396987319841187","first-page":"CD012144","article-title":"Antithrombotic treatment after stroke due to intracerebral haemorrhage","volume":"5","author":"Perry","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012113203713700_bibr65-2396987319841187","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1161\/STROKEAHA.114.006202","article-title":"Variation in restarting antithrombotic drugs at hospital discharge after intracerebral hemorrhage","volume":"45","author":"Pasquini","year":"2014","journal-title":"Stroke"},{"key":"2026012113203713700_bibr66-2396987319841187","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1212\/WNL.0000000000004235","article-title":"Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation","volume":"89","author":"Korompoki","year":"2017","journal-title":"Neurology"},{"key":"2026012113203713700_bibr67-2396987319841187","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ana.25079","article-title":"Oral anticoagulation and functional outcome after intracerebral hemorrhage","volume":"82","author":"Biffi","year":"2017","journal-title":"Ann Neurol"},{"key":"2026012113203713700_bibr68-2396987319841187","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0b013e3181dad605","article-title":"Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy","volume":"74","author":"Linn","year":"2010","journal-title":"Neurology"},{"key":"2026012113203713700_bibr69-2396987319841187","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s13063-015-0898-4","article-title":"Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial","volume":"16","author":"van Nieuwenhuizen","year":"2015","journal-title":"Trials"},{"key":"2026012113203713700_bibr70-2396987319841187","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4244\/EIJ-D-17-00201","article-title":"Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study","volume":"13","author":"Nielsen-Kudsk","year":"2017","journal-title":"EuroIntervention"},{"key":"2026012113203713700_bibr71-2396987319841187","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jgs.12799","article-title":"New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials","volume":"62","author":"Sardar","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"2026012113203713700_bibr72-2396987319841187","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2215\/CJN.03170509","article-title":"Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease","volume":"5","author":"Ananthapanyasut","year":"2010","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"key":"2026012113203713700_bibr73-2396987319841187","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"119","author":"Go","year":"2009","journal-title":"Circulation"},{"key":"2026012113203713700_bibr74-2396987319841187","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrneph.2012.160","article-title":"Anticoagulants in atrial fibrillation patients with chronic kidney disease","volume":"8","author":"Hart","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2026012113203713700_bibr75-2396987319841187","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.2165\/11635730-000000000-00000","article-title":"New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function","volume":"72","author":"Poulsen","year":"2012","journal-title":"Drugs"},{"key":"2026012113203713700_bibr76-2396987319841187","first-page":"S71","article-title":"Stroke prevention in atrial fibrillation patients with chronic kidney disease","volume":"29","author":"Hart","year":"2013","journal-title":"The Canadian Journal of Cardiology"},{"key":"2026012113203713700_bibr77-2396987319841187","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2010.12.013","article-title":"Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk","volume":"57","author":"Marinigh","year":"2011","journal-title":"J Am Coll  Cardiol"},{"key":"2026012113203713700_bibr78-2396987319841187","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"2026012113203713700_bibr79-2396987319841187","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"European Heart Journal"},{"key":"2026012113203713700_bibr80-2396987319841187","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"European Heart Journal"},{"key":"2026012113203713700_bibr81-2396987319841187","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1253\/circj.CJ-12-0899","article-title":"Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment","volume":"77","author":"Hori","year":"2013","journal-title":"Circ J"},{"key":"2026012113203713700_bibr82-2396987319841187","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"key":"2026012113203713700_bibr83-2396987319841187","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2026012113203713700_bibr84-2396987319841187","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.05.007","article-title":"Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease","volume":"21","author":"Eikelboom","year":"2012","journal-title":"Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association"},{"key":"2026012113203713700_bibr85-2396987319841187","first-page":"360","article-title":"Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care","author":"Kumar","year":"2018","journal-title":"BMJ"},{"key":"2026012113203713700_bibr86-2396987319841187","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pace.13331","article-title":"Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis","volume":"41","author":"Chokesuwattanaskul","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"key":"2026012113203713700_bibr87-2396987319841187","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(10)70104-6","article-title":"Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges","volume":"9","author":"Pantoni","year":"2010","journal-title":"Lancet Neurol"},{"key":"2026012113203713700_bibr88-2396987319841187","doi-asserted-by":"crossref","first-page":"h2484","DOI":"10.1136\/bmj.h2484","article-title":"Investigating intracerebral haemorrhage","volume":"350","author":"Wilson","year":"2015","journal-title":"BMJ"},{"key":"2026012113203713700_bibr89-2396987319841187","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","article-title":"Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration","volume":"12","author":"Wardlaw","year":"2013","journal-title":"Lancet Neurol"},{"key":"2026012113203713700_bibr90-2396987319841187","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1136\/heartjnl-2013-305151","article-title":"Brain MRI to personalise atrial fibrillation therapy: current evidence and perspectives","volume":"100","author":"Haeusler","year":"2014","journal-title":"Heart"},{"key":"2026012113203713700_bibr91-2396987319841187","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1212\/WNL.0000000000003183","article-title":"Recurrent stroke risk and cerebral microbleed burden in ischemic stroke and TIA: a meta-analysis","volume":"87","author":"Wilson","year":"2016","journal-title":"Neurology"},{"key":"2026012113203713700_bibr92-2396987319841187","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1212\/WNL.0000000000004704","article-title":"Brain microbleeds, anticoagulation, and hemorrhage risk: meta-analysis in stroke patients with AF","volume":"89","author":"Charidimou","year":"2017","journal-title":"Neurology"},{"key":"2026012113203713700_bibr93-2396987319841187","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S1474-4422(16)30213-7","article-title":"Worldwide collaboration in the Microbleeds International Collaborative Network","volume":"15","author":"Microbleeds International Collaborative N","year":"2016","journal-title":"Lancet Neurol"},{"key":"2026012113203713700_bibr94-2396987319841187","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2016.03.019","article-title":"Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study","volume":"178","author":"O'Donnell","year":"2016","journal-title":"Am Heart J"},{"key":"2026012113203713700_bibr95-2396987319841187","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007034","article-title":"Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) study","volume":"6","author":"Paciaroni","year":"2017","journal-title":"J Am Heart Assoc"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2396987319841187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2396987319841187","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/4\/3\/198\/64653135\/2396987319841187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/4\/3\/198\/64653135\/2396987319841187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:25:09Z","timestamp":1769019909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/4\/3\/198\/8275974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1177\/2396987319841187","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9,1]]},"published":{"date-parts":[[2019,9,1]]}}}